

# UNIVERSITY OF BIRMINGHAM

University of Birmingham  
Research at Birmingham

## Per-arnt-sim (PAS) domain-containing protein kinase is downregulated in human islets in type 2 diabetes and regulates glucagon secretion

da Silva Xavier, G; Farhan, H; Kim, H; Caxaria, S; Johnson, P; Hughes, S; Bugliani, M; Marselli, L; Marchetti, P; Birzele, F; Sun, G; Scharfmann, R; Rutter, J; Siniakowicz, K; Weir, G; Parker, H; Reimann, F; Gribble, F M; Rutter, G A

DOI:

[10.1007/s00125-010-2010-7](https://doi.org/10.1007/s00125-010-2010-7)

License:

Creative Commons: Attribution-NonCommercial (CC BY-NC)

### Document Version

Publisher's PDF, also known as Version of record

### Citation for published version (Harvard):

da Silva Xavier, G, Farhan, H, Kim, H, Caxaria, S, Johnson, P, Hughes, S, Bugliani, M, Marselli, L, Marchetti, P, Birzele, F, Sun, G, Scharfmann, R, Rutter, J, Siniakowicz, K, Weir, G, Parker, H, Reimann, F, Gribble, FM & Rutter, GA 2011, 'Per-arnt-sim (PAS) domain-containing protein kinase is downregulated in human islets in type 2 diabetes and regulates glucagon secretion', *Diabetologia*, vol. 54, no. 4, pp. 819-27.  
<https://doi.org/10.1007/s00125-010-2010-7>

[Link to publication on Research at Birmingham portal](#)

### Publisher Rights Statement:

Checked for eligibility: 19/06/2018

### General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

# Per-arnt-sim (PAS) domain-containing protein kinase is downregulated in human islets in type 2 diabetes and regulates glucagon secretion

G. da Silva Xavier · H. Farhan · H. Kim · S. Caxaria · P. Johnson · S. Hughes · M. Bugliani · L. Marselli · P. Marchetti · F. Birzele · G. Sun · R. Scharfmann · J. Rutter · K. Siniakowicz · G. Weir · H. Parker · F. Reimann · F. M. Gribble · G. A. Rutter

Received: 6 September 2010 / Accepted: 12 November 2010 / Published online: 23 December 2010  
© The Author(s) 2010. This article is published with open access at Springerlink.com

## Abstract

**Aims/hypothesis** We assessed whether per-arnt-sim (PAS) domain-containing protein kinase (PASK) is involved in the regulation of glucagon secretion.

**Methods** mRNA levels were measured in islets by quantitative PCR and in pancreatic beta cells obtained by laser capture microdissection. Glucose tolerance, plasma hor-

mone levels and islet hormone secretion were analysed in C57BL/6 *Pask* homozygote knockout mice (*Pask*<sup>-/-</sup>) and control littermates. Alpha-TC1-9 cells, human islets or cultured E13.5 rat pancreatic epithelia were transduced with anti-*Pask* or control small interfering RNAs, or with adenoviruses encoding enhanced green fluorescent protein or PASK.

---

H. Farhan and H. Kim contributed equally to this study.

**Electronic supplementary material** The online version of this article (doi:10.1007/s00125-010-2010-7) contains supplementary material, which is available to authorised users.

---

G. da Silva Xavier (✉) · H. Farhan · H. Kim · S. Caxaria · G. Sun · G. A. Rutter (✉)  
Section of Cell Biology, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Imperial College London, Exhibition Road, South Kensington, London SW7 2AZ, UK  
e-mail: g.dasilva-xavier@imperial.ac.uk

G. A. Rutter  
e-mail: g.rutter@imperial.ac.uk

P. Johnson · S. Hughes  
Nuffield Department of Surgical Sciences, Oxford University, Oxford, UK

M. Bugliani · L. Marselli · P. Marchetti  
Dipartimento di Endocrinologia e Metabolismo, Unità Metabolica, Università di Pisa, Pisa, Italy

F. Birzele  
Boehringer Ingelheim Pharma, Target Discovery Research, Ingelheim, Germany

R. Scharfmann  
INSERM U845, Centre de Recherche Croissance et Signalisation, Université Paris Descartes, Faculté de Médecine, Hôpital Necker, Paris, France

J. Rutter  
Division of Endocrinology, University of Utah School of Medicine, Salt Lake, UT, USA

K. Siniakowicz · G. Weir  
Section on Islet Transplantation and Cell Biology, Research Division, Joslin Diabetes Center and the Department of Medicine, Harvard Medical School, Boston, MA, USA

H. Parker · F. Reimann · F. M. Gribble  
Cambridge Institute for Medical Research and Department of Clinical Biochemistry, Addenbrooke's Hospital, Cambridge, UK

**Results** *PASK* expression was significantly lower in islets from human type 2 diabetic than control participants. *PASK* mRNA was present in alpha and beta cells from mouse islets. In *Pask*<sup>-/-</sup> mice, fasted blood glucose and plasma glucagon levels were 25±5% and 50±8% (mean ± SE) higher, respectively, than in control mice. At inhibitory glucose concentrations (10 mmol/l), islets from *Pask*<sup>-/-</sup> mice secreted 2.04±0.2-fold ( $p<0.01$ ) more glucagon and 2.63±0.3-fold ( $p<0.01$ ) less insulin than wild-type islets. Glucose failed to inhibit glucagon secretion from *PASK*-depleted alpha-TC1-9 cells, whereas *PASK* overexpression inhibited glucagon secretion from these cells and human islets. Extracellular insulin (20 nmol/l) inhibited glucagon secretion from control and *PASK*-deficient alpha-TC1-9 cells. *PASK*-depleted alpha-TC1-9 cells and pancreatic embryonic explants displayed increased expression of the preproglucagon (*Gcg*) and AMP-activated protein kinase (AMPK)-alpha2 (*Prkaa2*) genes, implying a possible role for AMPK-alpha2 downstream of *PASK* in the control of glucagon gene expression and release.

**Conclusions/interpretation** *PASK* is involved in the regulation of glucagon secretion by glucose and may be a useful target for the treatment of type 2 diabetes.

**Keywords** Alpha cells · Glucagon secretion · Human islets of Langerhans · Knockout mouse · *PASK*

## Abbreviations

AMPK	AMP-activated protein kinase
PAS	Per-arrnt-sim
PASK	PAS domain-containing protein kinase
<i>Pask</i> <sup>-/-</sup>	<i>Pask</i> homozygote knockout mice
siRNA	Small interfering RNA

## Introduction

Elevated glucose concentrations (>3.5 mmol/l) normally suppress the release of glucagon from pancreatic alpha cells; dysregulation of this process is a feature of type 1 and type 2 diabetes [1, 2]. Both direct [3] and indirect [4] effects of glucose on the release of glucagon have been described. Whereas the latter appear to involve the release of secretory products, including insulin [3, 5], gamma-aminobutyric acid [6–8] or zinc ions [4, 9] from neighbouring beta cells, as well as somatostatin from delta cells [10, 11], the signalling events involved in the direct sensing of glucose are more controversial [12]. These may involve enhanced metabolism of glucose and the closure of ATP-sensitive K<sup>+</sup> channels, followed by limited membrane depolarisation [13, 14]. AMP-activated protein kinase (AMPK) appears also to be involved in the regulation of glucagon release [15].

Per-arrnt-sim (PAS) domain-containing protein kinases (PASKs) are related to AMPK and are common in prokaryotes. However, there is currently only one known mammalian counterpart [16, 17]. We [18] and others [19, 20] have shown that *PASK* is important for energy sensing and maintenance of normal cellular energy balance in mammalian systems.

In pancreatic beta cells, *PASK* activity is regulated by glucose and is involved in the regulation of glucose-induced preproinsulin and pancreatic duodenum homeobox-1 (*Pdx1*) gene expression [18, 20]. Expression of the *Pask* gene in rodent islets and beta cell lines [18, 20] is also glucose-sensitive. Recently, *PASK* has been implicated in regulation of lipogenic gene expression [19] and might, therefore, influence glucose signalling through lipid intermediates as proposed for glucose-induced insulin secretion [21].

*Pask* homozygote knockout mice (*Pask*<sup>-/-</sup>), which are globally inactivated for *Pask*, have previously been reported to display lower plasma insulin levels than control littermates [19], but normal glucose tolerance [19, 22], reflecting enhanced insulin sensitivity [19]. Insulin secretion from *Pask*<sup>-/-</sup> islets has variously been shown to be not different [22] or lower [19] than in control islets. It has also been previously reported that total insulin content and/or beta cell mass were not altered in *Pask*<sup>-/-</sup> mice [19, 22]. However, data from these earlier studies are difficult to interpret for a number of reasons. In the first instance, total islet insulin was not always measured, making it difficult to evaluate the insulin secretory capacity of *Pask*<sup>-/-</sup> islets. Moreover quantification of beta cell mass using pancreatic sections is prone to substantial variability [19]. Due to these limitations [19, 22], the role of *PASK* in the regulation of pancreatic hormone release and glucose homeostasis remains to be clarified.

A recent report [20] showed that inhibition of insulin gene expression by palmitate was reversed by *Pask* overexpression in MIN6 beta cells. The loss of *PASK*, and hence the loss of regulation by *Pdx1* and *Mafa* gene expression [18], was proposed to be a mechanism by which insulin gene expression in the beta cell might be lost on exposure to palmitate [20]. Thus, *PASK* appears to exert a protective effect in mature beta cells. Moreover, aberrant *PASK* expression and/or function may play a significant role in the development of diabetes and, interestingly, *Pask*<sup>-/-</sup> mice develop glucose intolerance on a high-fat diet [18].

Although glucose homeostasis reflects the release of multiple islet hormones in addition to insulin, there are currently no published data on the role of *PASK* in other islet cell types. The present study demonstrates that *PASK* is involved in the regulation of glucagon secretion from pancreatic alpha cells. We show that *PASK* expression is decreased in the islets of human type 2 diabetic patients and that *Pask* is at least as strongly expressed in highly purified

mouse alpha cells as in beta cells. Silencing or ablation of *Pask* in clonal alpha cells or islets, respectively, drastically blunted the inhibition of glucagon secretion by glucose. Whereas the insulin content of PASK-deficient islets was dramatically reduced, the acute regulation of insulin secretion by glucose was normal. Thus, PASK regulates hormone release reciprocally from pancreatic alpha and beta cells. Given that dysregulation of insulin and glucagon secretion are characteristics of type 2 diabetes, we propose that PASK may be a potential drug target to modulate glucagon release in vivo.

## Methods

**Materials** Adenoviruses encoding for human *PASK* have been previously described [16]. All general chemicals and tissue culture reagents were purchased from Sigma (Poole, UK) or Invitrogen (Paisley, UK), unless otherwise stated in the text.

**Isolation and culture of islets** Studies on human islets were conducted with local ethics committee approval at all sites (Charing Cross Research Ethics Committee Ref. 07/H0711/114). Human islets were isolated as previously described in Oxford, UK [23], or in Pisa, Italy [24], and maintained in medium containing 11 mmol/l glucose for 10 days to allow the loss of exocrine tissue [25]. Human type 2 diabetic donors were selected according to established criteria [23, 26]. Mouse pancreatic islets were isolated and cultured as described in [3]. Alpha-TC1-9 cells (passage 35–45; American Type Culture Collection, Manassas, VA, USA) were cultured as previously described [7].

**Laser capture microdissection and microarray analysis** These procedures were performed as described in Electronic supplementary material (ESM) Methods.

**RNA sequencing** We prepared 300 ng of total RNA with a kit (mRNA-Seq 8; Illumina, Little Chesterford, UK). For clustering and sequencing we used Illumina cluster generation and sequencing kits v4. 9pM were loaded to the flowcell (one sample per lane) and sequenced on a sequencer (GAIIx) with RTA software version 2.6 (Little Chesterford, UK). On average we obtained 28 million reads per lane, passing Illumina's quality filtering. Short reads (35 bp) were aligned to the mouse genome (Ensembl v54) using a mapping station (Genomatix) [27] and to a database of known and potential splice junctions using Bowtie [28]. Up to three mismatches and no insertions or deletions were allowed, and, on average, more than 85% of the reads in a sample could be mapped to the genome. Gene expression

was measured as proposed by Mortazavi et al. [29] and reads per kilobase per million (RPKM) values were computed for every gene.

**Mice** *Pask*<sup>−/−</sup> mice (kindly provided by R. Wenger, Institute of Physiology and ZIHP, Zurich, Switzerland) [30] were back-crossed for ten generations with C57BL/6 mice prior to use. Mice were housed with two to five animals per cage in a pathogen-free facility on a 12 h light–dark cycle with free access to standard mouse chow diet, unless otherwise stated. All in vivo procedures were performed in the Imperial College Central Biomedical Service in accordance with the Principles of Laboratory Care and the UK Home Office (Animals Scientific Procedures Act, 1986), and approved by the local ethics committee. Genotyping was performed as previously described [30].

**Intraperitoneal glucose tolerance test** An intraperitoneal glucose tolerance test was performed on 8-week-old mice as described in [31], at 09:00 hours on each experimental day.

**Measurement of total pancreatic insulin and glucagon** Pancreases were excised from 8-week-old mice and suspended in ice-cold acid–ethanol (75.0% ethanol–23.4% molecular grade water–1.5% HCl–0.1% Triton X-100, vol./vol.) prior to disruption by sonication (microsonicator; Misonix, Farmingdale, NY, USA) at 4°C. Total protein was measured by Bradford's assay [32], and insulin and glucagon content were measured by radioimmunoassay (Linco, Watford, UK).

**Measurement of plasma glucagon** At 8 weeks of age mice were starved overnight prior to being killed by cervical dislocation. Blood (200 µl) was immediately removed by cardiac puncture. Plasma was collected using high-speed centrifugation (2,000 g, 5 min) in heparin-coated tubes (Microvette; Sarstedt, Leicester, UK) and plasma glucagon assessed by radioimmunoassay (Linco, Watford, UK).

**Manipulation of PASK content in alpha-TC1-9 cells and cultured islets of Langerhans** Alpha-TC1-9 cells and islets were infected with adenoviruses encoding for PASK or enhanced green fluorescent protein at a multiplicity of infection of 100 and cultured for 48 h prior to use. Alpha-TC1-9 cells were transfected with anti-*Pask* small interfering RNA (siRNA) or control siRNA (1 nmol/l) [18]. Protein content was assessed by western (immuno-)blot analysis.

**Culture of E13.5 rat pancreatic epithelia** E13.5 rat pancreatic epithelia were isolated and cultured as previously described [33]. Epithelia were cultured in the presence of anti-*Pask* siRNA or control siRNA [18] (1 nmol/l) for 10 days prior to RNA isolation for real-time quantitative PCR analysis.

**Real-time quantitative PCR analysis** Highly purified primary mouse islet beta and alpha cells were obtained by fluorescence-activated cell sorting of transgenic mice expressing the fluorescent protein Venus selectively in the alpha cell under the preproglucagon promoter [34, 35]. RNA was extracted from alpha-TC1-9 cells and cultured rat E13.5 explants using Trizol (Invitrogen) according to the manufacturer's guidelines. Total RNA was subjected to DNase treatment (Ambion, Warrington, UK), followed by cDNA conversion (high-capacity cDNA conversion kit; Applied Biosystems, Warrington, UK) and real-time quantitative PCR using SYBR green (Applied Biosystems) in a 7500 Real-Time PCR System (ABI, Warrington, UK).


**Western (immuno-)blot analysis** Western (immuno-)blot analysis was performed as previously described [18].

**Statistical analysis** Data are the means  $\pm$  SE for the number of observations indicated. Statistical significance and differences between means were assessed by Student's *t* test with Bonferroni correction for multiple analyses.

## Results

***PASK* gene expression is regulated by glucose in human pancreatic islets of Langerhans and is lowered in type 2 diabetes** We have previously shown that *Pask* mRNA and protein levels are increased by high glucose in rat islets and clonal MIN6 beta cells [18]. Here, we first determined whether islet *PASK* expression may also be regulated by glucose or by diabetes in humans. Measured in human islets of Langerhans by quantitative PCR, *PASK* mRNA was elevated after 24 h culture at 11 mmol/l glucose ( $2.7 \pm 0.2$ -fold vs culture at 3 mmol/l glucose [means  $\pm$  SE]; Fig. 1a). Measured after culture at 11 mmol/l glucose, *PASK* gene expression was significantly lower in islets from patients with type 2 diabetes than in control islets (Fig. 1b).

mRNA expression data obtained using whole islets may be confounded by variable degrees of contamination with other pancreatic cell types, as well as by other factors. Therefore, we sought to further support the above results by using laser capture microdissection and array analysis to quantify mRNA levels selectively in beta cell-enriched samples [26]. A clear tendency for decreased *PASK* expression in islets in type 2 diabetic pancreases vs controls was also observed using this approach (ESM Fig. 1). In contrast, consistent changes in levels of the AMPK- $\alpha$ 1 and - $\alpha$ 2 subunit (encoded by *PRKAA1* and *PRKAA2*, respectively) were not observed with array data on samples obtained by laser capture microdissection. However, with quantitative PCR done on the same samples with enough



**Fig. 1** *PASK* expression is regulated by glucose in human islets and is lowered in type 2 diabetic islets. Real-time quantitative PCR on non-diabetic (a, b) or type 2 diabetic (T2D) (b) human islet RNA, following culture at the indicated glucose concentrations for 24 h (a) or at 11 mmol/l glucose (b);  $n=3$ ; \* $p<0.05$ , \*\* $p<0.01$ . c *Pask* mRNA content in FACS-purified mouse alpha and beta cells; † $p=0.07$

RNA (10 vs 10), a small but statistically significant decrease in *PRKAA1* expression was apparent (18%;  $p<0.019$ ), using *RPL32* as an internal control.

***Pask* is expressed in murine pancreatic beta and alpha cells** In the mouse, *Pask* mRNA has previously been shown to be most abundant in testes as well as in haemopoietic tissues including thymus and spleen [30]. Levels in other tissues, including islets, are much lower [30] (G. A. Rutter and G. Sun, unpublished observations). Indeed, the expression of *Pask* in adult mouse islets and its induction by glucose have recently been questioned, since expression in these cells of the *lacZ* gene, expressed in mice null for *Pask* alleles under the *Pask* promoter, was barely detectable by beta-Gal staining [22]. By contrast, we have previously detected *Pask* mRNA in mouse islets and MIN6 cells [18], data recently confirmed by others [20]. Examined here in islets from mice on a mixed C57BL/6/sv129 background cultured at 11 mmol/l glucose, massive parallel sequencing (RNAseq) confirmed the presence of *Pask* mRNA at low but detectable levels, lying in the lower 30th percentile of all mRNAs at approximately  $0.2 \pm 0.3\%$  ( $n=3$  female mice) of  $\beta$ -actin mRNA levels (ESM Fig. 2).


To determine in which cell types *Pask* was expressed in mouse islets, we next compared the expression of *Pask* mRNA in highly purified primary mouse alpha and beta cells (Fig. 1c). These were obtained by fluorescence-activated cell sorting of transgenic mice selectively expressing the fluorescent protein, Venus, in the alpha cell [34, 35] and by real-time quantitative PCR analysis. This approach confirmed the presence of *Pask* mRNA in both cell types and indicated that levels in purified alpha cells ( $1.45 \pm$



0.46% of beta-actin mRNA) tended to be higher than in beta cells ( $0.54 \pm 0.044\%$ ;  $n=3$  preparations;  $p=0.07$  by two-tailed Student's  $t$  test).

*Pask<sup>-/-</sup> mice display normal glucose tolerance but impaired plasma glucagon concentration* Given the greater expression of *Pask* in alpha than in beta cells and the dysregulation of glucagon secretion observed in type 2 diabetes, as reviewed by others [2], we next analysed the potential contribution of this enzyme to the regulation of glucagon secretion using *Pask<sup>-/-</sup>* mice. At 8 weeks of age, *Pask<sup>-/-</sup>* male (Fig. 2a, c, e) and female (Fig. 2b, d) mice displayed  $25 \pm 5\%$  higher plasma glucose levels after 16 h of fasting than wild-type littermate control mice, but normal glucose tolerance after intraperitoneal injection of the sugar (Fig. 2a–d). Measured after fasting, plasma glucagon was significantly higher in *Pask<sup>-/-</sup>* male mice than in littermate controls ( $91 \pm 5.4$  vs  $58 \pm 3$  pg/ml; Fig. 2e).


*Islets of Langerhans from Pask<sup>-/-</sup> mice display impaired glucose-regulated glucagon secretion* We next examined



**Fig. 2** *Pask<sup>-/-</sup>* mice display higher fasted glucose levels than littermate controls. At 8 weeks of age, male (**a**, **c**) and female (**b**, **d**) *Pask<sup>-/-</sup>* mice were starved for 16 h prior to an intraperitoneal glucose tolerance test (1 g glucose per kg body weight). **c**, **d** Blood glucose at 0 min, as indicated by dotted squares (**a**, **b**), for male and female mice, respectively. **e** Plasma glucagon concentrations from male mice following 16 h of fasting.  $n=8$ –10 mice per group; \* $p<0.05$ , \*\* $p<0.01$ . Black squares and solid lines, *Pask<sup>+/+</sup>*, wild-type; rhombuses and dotted lines, *Pask<sup>+/-</sup>*, heterozygote; black triangles and dashed lines, *Pask<sup>-/-</sup>*, homozygous knockout

whether the elevated plasma glucagon concentration was due to dysregulation of alpha cell function. Supporting this view, the inhibition of glucagon secretion in response to elevated glucose was impaired in islets from *Pask<sup>-/-</sup>* mice (Fig. 3a). Thus, *Pask<sup>-/-</sup>* islets, in which *Pask* gene expression was undetectable (Fig. 3e), secreted  $2.04 \pm 0.2$ -fold more glucagon at inhibitory (10 mmol/l) glucose concentrations than did islets from wild-type littermates (Fig. 3a), whereas release at stimulatory (0.5 mmol/l) glucose was unaltered. Interestingly, a slight inhibitory effect on glucagon secretion in *Pask<sup>-/-</sup>* islets was still observed at 10 mmol/l glucose (Fig. 3a). Although glucose-stimulated insulin release when normalised to total islet insulin content was not affected by *Pask* deletion (Fig. 3b), the total amount of insulin per islet was lower ( $0.38 \pm 0.3$ -fold) in *Pask<sup>-/-</sup>* than in wild-type islets (Fig. 3d), i.e. the amount of insulin release was compromised in *Pask<sup>-/-</sup>* islets, in agreement with published data [19].


The expression of mouse preproinsulin 2 (*Ins2*) and *Pdx1* genes was strongly impaired in *Pask<sup>-/-</sup>* mouse islets (Fig. 3e), as previously reported [18, 20]. Moreover, the



**Fig. 3** Islets from *Pask<sup>-/-</sup>* mice display abnormal inhibition of glucagon secretion in response to glucose. **a** Glucagon and **(b)** insulin secretion in response to glucose was assessed in groups of ten mouse islets, as previously described [7]. Data presented as e% secreted hormone/total hormone content in 10 islets. White bars, islets exposed to 0.5 mmol/l glucose; black bars, islets exposed to 10 mmol/l glucose. **c** Total glucagon and **(d)** insulin from mouse islets of each genotype.  $n=3$  separate preparations of islets. **e** Total RNA was extracted from groups of 100 islets using Tri-reagent (Invitrogen) and gene expression analysed by real-time quantitative PCR analysis using SYBR-green (Applied Biosystems). Cyclophilin gene expression was used as the internal calibrator.  $n=3$  Nd, not detected; black bars, *Pask<sup>+/+</sup>* wild-type islets; grey bars, *Pask<sup>+/-</sup>* heterozygote islets; white bars, *Pask<sup>-/-</sup>* homozygous knockout mice islets. \* $p<0.05$ , \*\* $p<0.01$

insulin content of whole *Pask*<sup>-/-</sup> mouse pancreases was  $1.98 \pm 0.3$ -fold lower than that of wild-type pancreases ( $67 \pm 15$  vs  $133 \pm 12$  ng/mg protein for *Pask*<sup>-/-</sup> and wild-type mice, respectively;  $n=3$  mice for each genotype). While glucagon protein content in *Pask*<sup>-/-</sup> islets (Fig. 3c) was unaffected, preproglucagon (*Gcg*) gene expression was slightly but significantly increased, as was *Prkaa2* mRNA expression (Fig. 3e).

**Glucagon release is activated in the absence of *Pask* in alpha-TC1-9 cells** Since the above experiments using intact islets did not allow ready discrimination between an action of PASK cell-autonomously in the alpha cell and an effect mediated by changes in the release of beta cell-derived factors, we next explored the role of the enzyme in the clonal alpha-TC1-9 cell line [3]. Culture of alpha-TC1-9 cells in the presence of an siRNA against *Pask* led to near complete ablation of *Pask* gene expression and protein content (Fig. 4a). Glucagon release from *Pask*-deficient alpha-TC1-9 cells at inhibitory (10 mmol/l) glucose concentrations was comparable to that observed in control cells at stimulatory (0.5 mmol/l) glucose concentrations (Fig. 4b). By contrast, addition of extracellular insulin (20 nmol/l) led to inhibition of glucagon secretion in control and *Pask*-silenced alpha-TC1-9 cells, indicating (1) the presence of distinct glucose and insulin signalling pathways in the alpha cell and (2) that the insulin signalling pathway in *Pask*-silenced alpha-TC1-9 cells was intact (Fig. 4b). Total glucagon protein content, as assessed by radioimmunoassay, was not different between alpha-TC1-9 cells treated with control or anti-*Pask* siRNA (data not shown).



**Fig. 4** PASK silencing activates glucagon secretion in alpha-TC1-9 cells. **a** Transfection of alpha-TC1-9 cells with 1 nmol/l *Pask* siRNA led to decreased *Pask* expression and PASK protein content, as assessed by real-time quantitative PCR and western (immuno-)blot analysis. The migration of molecular weight markers (BioRad, Hemel Hempstead, UK) is indicated on the western (immuno-)blot. **b** Glucagon secretion in response to elevated glucose and insulin was assessed as described in Fig. 3,  $n=3$ . Data presented are % secreted hormone/total hormone content per sample. White bars, transfected with control; grey bars, transfected with anti-*Pask* siRNA. \* $p<0.05$ , \*\* $p<0.01$

**Glucagon release is inhibited by PASK overexpression in alpha-TC1-9 cells and human islets of Langerhans** The above findings indicated that PASK may be an inhibitor of glucagon release from alpha cells. To test this hypothesis, we next explored the impact of forced activation of the enzyme in these cells. Adenovirus-mediated overexpression of PASK in alpha-TC1-9 cells (Fig. 5a) led to inhibition of glucagon secretion at normally stimulatory (1 mmol/l) glucose concentrations ( $0.36 \pm 0.1$ -fold vs control).


Similarly, overexpression of PASK in human islets of Langerhans (Fig. 5b) inhibited glucagon secretion at all glucose concentrations tested, while the stimulatory effects of KCl were largely maintained. Interestingly, there was still an apparent effect of glucose on glucagon secretion in human islets overexpressing PASK (Fig. 5b), consistent with a maintained effect on glucagon release mediated by beta cell-derived factors.

**Silencing of *Pask* gene expression in alpha-TC1-9 cells and E13.5 rat pancreatic epithelial explants causes increased AMPK-alpha2 and glucagon gene expression** In an effort to identify the mechanism(s) through which PASK may regulate glucagon secretion, we measured the expression of a number of potential target genes. *Pask* gene expression was inhibited in alpha-TC1-9 cells treated with a siRNA against *Pask* (Fig. 6). In line with the above findings in *Pask*<sup>-/-</sup> mouse islets (Fig. 3e), preproglucagon (*Gcg*) gene expression was increased substantially by *Pask* ablation in alpha-TC1-9 cells ( $7.4 \pm 1.3$ -fold vs control; Fig. 6a), although total glucagon protein content was unaltered (Fig. 2c), consistent with the relatively slow turnover of mature glucagon. *Prkaa2* (Fig. 6a), but not *Prkaa1* (data not shown) gene expression was also increased ( $4.3 \pm 1.5$ -fold vs control) by *Pask* silencing.

To determine whether the dysregulation of glucagon gene expression and release in *Pask*<sup>-/-</sup> mice was due to a role of the enzyme in the development of pancreatic alpha and beta cells, we next examined the impact of *Pask* silencing in developing pancreatic epithelia. E13.5 rat pancreatic epithelial explants [33], in which *Pask* gene expression was silenced with an anti-*Pask* siRNA, developed endocrine buds to an extent indistinguishable from that observed in explants treated with a control (scrambled) siRNA (ESM Fig. 3). However, explants in which *Pask* was silenced displayed similar increases in *Gcg* and *Prkaa2* gene expression (ESM Fig. 3) to those observed in alpha-TC1-9 cells (Fig. 6). Explants overexpressing *Pask* did not survive the 10 day culture period.

## Discussion

The present data indicate that PASK/*Pask* is expressed in human and mouse pancreatic islets, respectively, and




**Fig. 5** Overexpression of PASK inhibits glucagon secretion in alpha-TC1-9 cells and human islets of Langerhans. **a** Alpha-TC1-9 cells were infected with adenovirus encoding for *PASK* (grey bars) or enhanced green fluorescent protein (EGFP; control virus, white bars) at multiplicity of infection of 100 and cultured for 24 h prior to glucagon secretion as described in Fig. 3,  $n=3$ . **b** Human islets of Langerhans were infected with adenovirus for human *PASK* or EGFP at multiplicity of infection of 100 and cultured for 48 h prior to

glucagon secretion assay [3],  $n=3$ . Data presented are % secreted hormone/total hormone content per sample. **c** Western (immuno-)blot analysis of protein extracts from alpha-TC1-9 cells and human pancreatic islets after 48 h transduction with adenoviruses encoding for *PASK* or EGFP. *PASK* protein content was normalised to tubulin protein content as assessed by densitometry using ImageJ (<http://rsbweb.nih.gov/ij/index.html>;  $n=3$ ). Representative images from at least three separate preparations of each are shown. \* $p<0.05$ , \*\* $p<0.01$


regulated by glucose. Moreover, in the mouse, *Pask* mRNA levels are at least as high in alpha cells as in beta cells. Correspondingly, we provide evidence that changes in *Pask* gene expression within the islet regulate both insulin content [18, 20] and glucagon release, i.e. that *PASK* mediates a ‘high glucose’ signal in alpha and beta cells. In the alpha cell, this might be achieved either via a cell-autonomous action on cellular activity and/or through changes in the release of beta cell-derived factors (Fig. 7). Either of these mechanisms are likely to modulate intracellular signalling within the alpha cell through changes in membrane excitability, levels of unbound  $\text{Ca}^{2+}$ , cAMP, etc.

*PASK is expressed in pancreatic islets* An important finding of the present study is that *Pask* mRNA is clearly



**Fig. 6** *Pask* silencing in alpha-TC1-9 cells leads to increased expression of *Gcg* and *Prkaa2*. Real-time quantitative PCR analysis, using SYBR green (Applied Biosystems), of RNA from alpha-TC1-9 cells treated with control or *Pask* siRNA,  $n=3$ . Cyclophilin gene expression was used as the internal calibrator for real-time quantitative PCR. White bars, treated with control; grey bars, treated with anti-*Pask* siRNA. \*\* $p<0.01$

present in mouse islets maintained at permissive glucose concentrations (11 mmol/l), in contrast to a recent suggestion [22]. These results and those from another recent publication [20] support our own previous findings [18]. We would stress, however, that the level of gene expression, at least at the mRNA level, was relatively low compared with tissues in which *Pask* is strongly expressed (notably in the testes) [22], an observation that probably underlies the failure to detect significant expression using alternative approaches [22].



**Fig. 7** Proposed mechanism for *PASK* action in alpha cells. Glucagon secretion is regulated by changes in extracellular glucose and other factors, including insulin and possibly other molecules released from pancreatic beta cells. We propose (dashed lines) that *PASK* may be involved in cell-autonomous regulation of glucagon secretion, possibly through the regulation of *Prkaa2* gene expression (AMPK- $\alpha$ 2) (1) and/or an as yet unidentified pathway (2). *PASK* may also regulate glucagon secretion through its action on beta cell function and/or beta cell mass (3)



**PASK regulates insulin and glucagon secretion** It has previously been shown that islet architecture and beta cell mass in *Pask*<sup>-/-</sup> mice are intact [19, 22]. Thus, it was hypothesised in earlier studies that the observed decrease in insulin release may have been due to defective glucose-signalling in the beta cell [19]. In contrast, our data show that glucose-regulated insulin secretion was intact in *Pask*<sup>-/-</sup> islets (Fig. 3b), but that the insulin content of the islet (Fig. 3d) and pancreas (see Results section) were lowered by *Pask* deletion. This apparent discrepancy between the present and earlier [19, 22] studies may reflect differences in the genetic background, age and sex of the mice used. We would, however, note that *Pask*<sup>-/-</sup> beta cell mass was previously assessed by immunohistochemical analysis of fixed pancreatic sections, which may be prone to error.

Nevertheless, it was previously reported that plasma insulin content was compromised in *Pask*<sup>-/-</sup> mice [19], a result consistent with the present findings. In our hands, glucagon release from *Pask*<sup>-/-</sup> mouse islets (Fig. 3a) and human islets in which PASK was overexpressed (Fig. 5b) still displayed some degree of glucose-responsiveness, even though this was markedly decreased compared with the control condition. We hypothesise that this ‘residual’ regulation of release may be due, at least in part, to the release of insulin or other factors (Zn<sup>2+</sup>, gamma-aminobutyric acid, etc.) from neighbouring pancreatic beta cells and is consistent with the maintained effect of exogenous insulin on glucagon release from alpha-TC1-9 cells (Fig. 4b).

Close inspection of the data of Fig. 3a vs Fig. 4 reveals that whereas loss of *Pask* enhanced glucagon secretion from islets only at high (inhibitory) glucose levels (Fig. 3a), stimulation of glucagon release was apparent at all glucose concentrations examined in alpha-TC1-9 cells (Fig. 4). The mechanisms responsible for this difference are unclear. However, we note that while insulin mRNA was present at low but detectable levels in control alpha-TC1-9 cells (C<sub>t</sub> values ≥29; data not shown), silencing of *Pask* led to decreased insulin gene expression such that this was below the limit of detection. Hence an action of *Pask* silencing on endogenous insulin secretion from alpha-TC1-9 cells, and thus loss of tonic inhibition of glucagon secretion by this hormone, may contribute to the above mechanisms. Further studies are needed to resolve this question.

Interestingly, the increase in plasma glucagon levels measured after 16 h fasting in 8-week-old *Pask*<sup>-/-</sup> mice was similar to that observed in alpha cell-specific insulin receptor knockout mice of the same age [5]. We have previously shown that PASK activity is not regulated by insulin, but that PASK may regulate insulin gene expression in pancreatic beta cells [18]. Thus, we propose that the regulation of insulin content by *Pask* is one of the mechanisms through which PASK may indirectly regulate glucagon release.

**A role for AMPK alpha2 downstream of PASK?** Our gene-expression studies revealed that expression of the catalytic subunit of another glucose-responsive fuel gauge, *Prkaa2* (encoding AMPK-alpha2), is upregulated when *Pask* gene expression is compromised (Fig. 6). This is an interesting observation, since AMPK activity has been shown to be glucose-responsive in pancreatic beta cells [36] and to regulate insulin release [37, 38]; in addition, we have recently shown that activation of AMPK in the alpha cell stimulates glucagon secretion [15]. However, as also observed here, *Prkaa2* mRNA levels are normally much lower (more than tenfold) than *Prkaa1* in purified mouse beta and alpha cells [31], suggesting that the inappropriate activation of this isoform and an increase in AMPK activity in the nucleus (from which AMPK alpha1 is excluded in mature pancreatic endocrine cells) [36] may impact on the transcription of key genes, including *Gcg*, to reprogram the alpha cell. Interestingly, induction of *Prkaa2* expression was also observed in E13.5 pancreatic epithelia [33] in which *Pask* was silenced (Fig. 6c), indicating that defects during pancreatic development may contribute to the dysregulation of glucagon release in *Pask*<sup>-/-</sup> mice.

**PASK may have a role in the pathophysiology of type 2 diabetes** The observation that pancreatic islets from patients with type 2 diabetes display lower PASK mRNA levels than islets from non-diabetic individuals (Fig. 1b) suggests that lowered PASK activity may contribute to decreased insulin release and to enhanced glucagon secretion in this condition [1]. PASK may therefore represent a potential therapeutic target, the activation of which might favourably affect the secretion of both hormones in patients with type 2 diabetes.

**Acknowledgements** The authors thank S. Vakhshouri for technical assistance, and F. Semplici and M. K. Loder for scientific input during manuscript preparation. This work was supported by a Juvenile Diabetes Research Foundation post-doctoral fellowship and an European Foundation for the Study of Diabetes Albert Renold travelling fellowship to G. da Silva Xavier, and by grants to G. A. Rutter from the Wellcome Trust (081958/2/07/2) and the Medical Research Council (G0401641). H. Farhan, H. Kim and S. Caxaria were supported by Imperial College London BSc and MSc project funds. The Diabetes Research and Wellness Foundation supported P. Johnson and S. Hughes.

**Duality of interest** The authors declare that there is no duality of interest associated with this manuscript.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

## References

1. Unger RH (1985) Glucagon physiology and pathophysiology in the light of new advances. *Diabetologia* 28:574–578

2. Gromada J, Franklin I, Wollheim CB (2007) Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. *Endocr Rev* 28:84–116
3. Ravier MA, Rutter GA (2005) Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic alpha-cells. *Diabetes* 54:1789–1797
4. Ishihara H, Maechler P, Gjinovci A, Herrera PL, Wollheim CB (2003) Islet beta-cell secretion determines glucagon release from neighbouring alpha-cells. *Nat Cell Biol* 5:330–335
5. Kawamori D, Kurpad AJ, Hu J et al (2009) Insulin signaling in alpha cells modulates glucagon secretion in vivo. *Cell Metab* 9:350–361
6. Rorsman P, Berggren PO, Bokvist K et al (1989) Glucose-inhibition of glucagon secretion involves activation of GABAA-receptor chloride channels. *Nature* 341:233–236
7. Bailey SJ, Ravier MA, Rutter GA (2007) Glucose-dependent regulation of gamma-aminobutyric acid (GABA A) receptor expression in mouse pancreatic islet alpha-cells. *Diabetes* 56:320–327
8. Gilon P, Bertrand G, Loubatieres-Mariani MM, Remacle C, Henquin JC (1991) The influence of gamma-aminobutyric acid on hormone release by the mouse and rat endocrine pancreas. *Endocrinology* 129:2521–2529
9. Zhou H, Zhang T, Harmon JS, Bryan J, Robertson RP (2007) Zinc, not insulin, regulates the rat alpha-cell response to hypoglycemia in vivo. *Diabetes* 56:1107–1112
10. Gromada J, Hoy M, Buschard K, Salehi A, Rorsman P (2001) Somatostatin inhibits exocytosis in rat pancreatic alpha-cells by G(i2)-dependent activation of calcineurin and depriming of secretory granules. *J Physiol* 535:519–532
11. Hauge-Evans AC, King AJ, Carmignac D et al (2009) Somatostatin secreted by islet delta-cells fulfills multiple roles as a paracrine regulator of islet function. *Diabetes* 58:403–411
12. Rutter GA (2009) Regulating glucagon secretion: somatostatin in the spotlight. *Diabetes* 58:299–301
13. Gopel SO, Kanno T, Barg S, Weng XG, Gromada J, Rorsman P (2000) Regulation of glucagon release in mouse -cells by KATP channels and inactivation of TTX-sensitive Na<sup>+</sup> channels. *J Physiol* 528:509–520
14. MacDonald PE, de Marinis YZ, Ramacheya R et al (2007) A K ATP channel-dependent pathway within alpha cells regulates glucagon release from both rodent and human islets of Langerhans. *PLoS Biol* 5:e143
15. Leclerc I, Sun G, Morris C, Fernandez-Milan E, Nyirenda M, Rutter GA (2011) AMP-activated protein kinase regulates glucagon secretion from mouse pancreatic alpha cells. *Diabetologia* 54:125–134
16. Rutter J, Michnoff CH, Harper SM, Gardner KH, McKnight SL (2001) PAS kinase: an evolutionarily conserved PAS domain-regulated serine/threonine kinase. *Proc Natl Acad Sci USA* 98:8991–8996
17. Hofer T, Spielmann P, Stengel P et al (2001) Mammalian PASKIN, a PAS-serine/threonine kinase related to bacterial oxygen sensors. *Biochem Biophys Res Commun* 288:757–764
18. da Silva XG, Rutter J, Rutter GA (2004) Involvement of Per-Arnt-Sim (PAS) kinase in the stimulation of preproinsulin and pancreatic duodenum homeobox 1 gene expression by glucose. *Proc Natl Acad Sci USA* 101:8319–8324
19. Hao HX, Cardon CM, Swiatek W et al (2007) PAS kinase is required for normal cellular energy balance. *Proc Natl Acad Sci USA* 104:15466–15471
20. Fontes G, Semache M, Hagman DK et al (2009) Involvement of Per-Arnt-Sim kinase and extracellular-regulated kinases-1/2 in palmitate inhibition of insulin gene expression in pancreatic beta-cells. *Diabetes* 58:2048–2058
21. Corkey BE, Deeney JT, Yaney GC, Tornheim K, Prentki M (2000) The role of long-chain fatty acyl-CoA esters in beta-cell signal transduction. *J Nutr* 130:299S–304S
22. Bortner E, Niessen M, Zuellig R et al (2007) Glucose-stimulated insulin production in mice deficient for the PAS kinase PASKIN. *Diabetes* 56:113–117
23. Cross SE, Hughes SJ, Partridge CJ, Clark A, Gray DW, Johnson PR (2008) Collagenase penetrates human pancreatic islets following standard intraductal administration. *Transplantation* 86:907–911
24. Marchetti P, Bugliani M, Lupi R et al (2007) The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients. *Diabetologia* 50:2486–2494
25. Leclerc I, Woltersdorf WW, da Silva XG et al (2004) Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion. *Am J Physiol Endocrinol Metab* 286:E1023–E1031
26. Marselli L, Thorne J, Dahiya S et al (2010) Gene expression profiles of beta-cell enriched tissue obtained by laser capture microdissection from subjects with type 2 diabetes. *PLoS ONE* 5:e11499
27. Sultan M, Schulz MH, Richard H et al (2008) A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. *Science* 321:956–960
28. Langmead B, Trapnell C, Pop M, Salzberg SL (2009) Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol* 10:R25
29. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B (2008) Mapping and quantifying mammalian transcriptomes by RNA-Seq. *Nat Methods* 5:621–628
30. Katschinski DM, Marti HH, Wagner KF et al (2003) Targeted disruption of the mouse PAS domain serine/threonine kinase PASKIN. *Mol Cell Biol* 23:6780–6789
31. Sun G, Tarasov AI, McGinty J et al (2010) Ablation of AMP-activated protein kinase alpha1 and alpha2 from mouse pancreatic beta cells and RIP2.Cre neurons suppresses insulin release in vivo. *Diabetologia* 53:924–936
32. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 72:248–254
33. Miralles F, Serup P, Cluzeaud F, Vandewalle A, Czernichow P, Scharfmann R (1999) Characterization of beta cells developed in vitro from rat embryonic pancreatic epithelium. *Dev Dyn* 214:116–126
34. Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, Gribble FM (2008) Glucose sensing in L cells: a primary cell study. *Cell Metab* 8:532–539
35. Nicolson TJ, Bellomo EA, Wijesekara N et al (2009) Insulin storage and glucose homeostasis in mice null for the granule zinc transporter ZnT8 and studies of the type 2 diabetes-associated variants. *Diabetes* 58:2070–2083
36. da Silva Xavier G, Leclerc I, Salt IP et al (2000) Role of AMP-activated protein kinase in the regulation by glucose of islet beta cell gene expression. *Proc Natl Acad Sci USA* 97:4023–4028
37. da Silva XG, Leclerc I, Varadi A, Tsuboi T, Moule SK, Rutter GA (2003) Role for AMP-activated protein kinase in glucose-stimulated insulin secretion and preproinsulin gene expression. *Biochem J* 371:761–774
38. Tsuboi T, da Silva XG, Leclerc I, Rutter GA (2003) 5'-AMP-activated protein kinase controls insulin-containing secretory vesicle dynamics. *J Biol Chem* 278:52042–52051